Fate Therapeutics Inc (FATE) stock news · rev $6.6M
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
This FATE news page leads with what Fate Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for FATE yet. We will not pad this page with generic market recap.
Latest reported FATE revenue for 2025-12-31 was $6.6M. Net income was -$136.3M. Revenue was down 51.2% from 2024-12-31 to 2025-12-31. FATE currently screens at market cap $331.0M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the FATE stock page; for the tape open the quote page.
FATE stock news FAQ
What are FATE's latest revenue and net income?
Latest cached Fate Therapeutics Inc (FATE) revenue for Dec 31, 2025 was $6.6M. Net income was -$136.3M. Statements: https://lician.com/financials/fate
How did FATE revenue change from the prior cached period?
Cached Fate Therapeutics Inc (FATE) revenue was down 51.2% from $13.6M (Dec 31, 2024) to $6.6M (Dec 31, 2025). Statements: https://lician.com/financials/fate
What is FATE's market cap?
Fate Therapeutics Inc (FATE) market cap is $331.0M on the latest cached fundamentals snapshot.
What kind of company is FATE?
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
Where is FATE stock news listed?
Cached stock news for Fate Therapeutics Inc (FATE) is listed at https://lician.com/news/fate. Filings: https://lician.com/sec/fate
Not investment advice.